76 A recent cluster-randomised controlled trial conducted in Linqu County, China, has provided fresh insights into the benefits of Helicobacter pylori (H. pylori) eradication as a strategy for gastric cancer prevention. The study, encompassing a broad population base, focused on determining the effectiveness of this intervention in a high-risk region, offering a valuable perspective on the potential public health implications. The findings were published in the journal Nature Medicine. Gastric cancer remains a leading cause of cancer-related deaths globally, with East Asia being particularly affected. H. pylori, a bacterium prevalent in over 40% of the global population, is recognised as a significant risk factor for gastric cancer. The bacterium’s eradication has been suggested as a preventive measure, yet prior studies have been limited in scale and duration. To address this, the current study implemented a community-based approach, involving 180,284 eligible participants from 980 villages, aged between 25 and 54 years. A block-stratified, cluster-randomisation method was used to put villages into one of two groups. One group had a 10-day quadruple therapy with omeprazole, tetracycline, metronidazole, and bismuth citrate. The other group got omeprazole and bismuth citrate to ease their symptoms. Participants who tested negative for H. pylori did not receive any treatment. The study’s primary outcome was the incidence of gastric cancer over a follow-up period of nearly 12 years. The results revealed a modest reduction in gastric cancer incidence among those receiving the anti-H. pylori treatment, compared to the control group. Specifically, the hazard ratio (HR) for gastric cancer incidence was 0.86 (95% confidence interval [CI]: 0.74–0.99) for the intention-to-treat analysis. A more pronounced benefit was observed in individuals who successfully eradicated H. pylori, with an HR of 0.81 (95% CI: 0.69–0.96). The study documented 1,035 cases of incident gastric cancer, highlighting the substantial burden of this disease in the region. Interestingly, the study found that getting rid of H. pylori had a bigger protective effect on people younger than 45 years old, with a 35% lower risk of getting gastric cancer and a 43% lower risk of death after successful eradication. In contrast, the benefit for participants aged 45–54 years, while suggestive, was not statistically significant. These findings underscore the potential advantage of early intervention in the progression of precancerous lesions. Despite the positive outcomes, the study observed moderate adverse effects in 1,345 participants during the 10-day treatment, although no severe adverse events were reported. This underscores the need for careful consideration of the risks and benefits when implementing mass eradication programmes. The study mostly looked at non-cardia gastric cancer, but it also showed that more research needs to be done to find out how getting rid of H. pylori affects cardia gastric cancer and other conditions that are similar. The findings align with previous studies indicating that the eradication of H. pylori can significantly reduce the risk of gastric cancer, particularly in high-risk populations. The study concludes with a call for cautious optimism regarding the implementation of H. pylori screening and eradication as a public health strategy. The evidence supports the potential for significant reductions in gastric cancer incidence and mortality, particularly with early intervention. However, it also highlights the importance of tailored strategies that consider individual risk factors and the broader epidemiological context. This landmark trial, with its extensive follow-up and large-scale design, provides robust evidence supporting the role of H. pylori eradication in gastric cancer prevention. The results could inform public health policies, especially in regions with high gastric cancer prevalence, where such interventions could significantly impact public health outcomes.